Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements from Zelluna and BC Platforms.
The number of products in active development by the pharma and biotech industries has topped 15,000 for the first time but the rate of the pipeline growth has slowed to just 2.7%, the lowest for five years, shows a new analysis by Citeline.
As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.
As Novartis prepares its imminent US filing for its Gilenya follow-up siponimod some experts are underwhelmed by its pivotal EXPAND study.
The T-cell therapy company has been tipped as a potential leader in a potentially disruptive field as new data support wide application in cancer.